Cryogenic Valve for Pharmaceutical Market Size - By Valve Type, By Valve Size, By Application, Distribution Channel, Analysis, Share, Growth Forecast, 2025 - 2034

Cryogenic Valve for Pharmaceutical Market Size

The cryogenic valve for pharmaceutical market was estimated at USD 577.3 million in 2024. The market is expected to grow from USD 619.9 million in 2025 to USD 1.19 billion in 2034, at a CAGR of 7.5%, according to latest report published by Global Market Insights Inc.

With growing importance of specialty gases like oxygen, argon and liquid nitrogen for advanced applications like drug preservation, storage of vaccines and biotech research, the cryogenic valve is gaining importance due to such important applications within the pharmaceutical industry. Since the production of these gases requires low temperatures, cryogenic valves can provide a sterile environment and help in delivering these gases efficiently.
 

Prominent manufacturers, including Parker Hannifin, Velan, and Samson AG, are actively innovating valve designs to meet stringent industry standards. For instance, Parker Hannifin reported a 12% increase in its cryogenic product sales in 2023, reflecting the growing adoption of these systems.
 

In 2023, the European Industrial Gases Association (EIGA) reported a 15% reduction in industrial emissions across European pharmaceutical facilities, driven by improved energy efficiency and gas handling protocols in cryogenic systems. Additionally, the U.S. Environmental Protection Agency (EPA) enforces Effluent Guidelines (40 CFR Part 439) and NESHAP standards (40 CFR Part 63) for pharmaceutical manufacturing, indirectly encouraging the adoption of cryogenic systems by promoting cleaner and more efficient production environments.
 

Further, Air Separation Units (ASUs) being essential for producing high-purity gas are used in healthcare, particularly across pharmaceuticals. For instance, China’s steel industry, which produced over 1,005 million tons of crude steel in 2024, consumed more than 55 billion cubic meters of oxygen annually. With such a need for large scale cryogenic valves, the demand has helped manufacturers like Crane Company, Tecnocryo, and Flowserve to widen their product portfolio to match the infrastructure growth
 

With respect to the production of crucial mRNA and other biological vaccine, cryogenic valves are helping in keeping the required temperature, maintaining integrity and compliance requirement for such delicate materials. This trends directly gained momentum since 2021, with the development of vaccines pertaining to the COVID-19 pandemic. According to the International Air Transport Association (IATA), global pharmaceutical cold chain logistics market which was valued at USD 18.61 billion in 2024. has been growing steadily, driven by the increasing demand for temperature-sensitive biologics.
 

Cryogenic Valve for Pharmaceutical Market Trends

Advancement in technology has helped the market grow, with innovation in cryogenic valves has further improved efficiency as well as the precision that is required for its use in the pharmaceutical industry and process.
 

• With the focus on cryogenic gases like oxygen and liquid nitrogen, the pharma industry is highly dependent on these gases due to its application across the industry. This dependency has further increased production therefore, the need for cryogenic valves. These valves play an important role in meeting up with the global standards like the ASME-BPE and FDA standards for leak prevention, material compatibility and cleanliness. International Institute of Refrigeration (IIR) reports that the healthcare and pharmaceutical sectors are witnessing a 15% annual growth in cryogenic technology adoption, showing the growing reliance on these systems to meet evolving industry needs.
   
• Leading manufacturers, including Emerson Electric Co., Parker Hannifin Corporation, and Cryocomp, are contributing to this growth by developing advanced cryogenic valve solutions that are meant for biopharmaceutical applications. Emerson through their AEV ²XC Cryogenic C-Ball Valve series offers a unique ball design that ensures zero leakage, low emissions, and bidirectional flow, making it ideal for sterile gas isolation in pharma environments.
   
• In cell preservation as well as gene therapy, the U.S. Food and Drug Administration (FDA) reports that during 2023, there was an increase of over 20% for cryogenic preservation application, showing its growing importance within the healthcare and pharma sector for cryogenic valves. These developments are supporting the growth of the cryogenic infrastructure within the biopharma sector.
   

Cryogenic Valve for Pharmaceutical Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on valve type, the market is segmented into ball valve, diaphragm valves, globe valve, check valve, others (relief, safety, solenoid valve etc.). The ball valve segment held dominant market share, generating a revenue of USD 208.6 million in 2024. This dominance is due to its sealing capabilities as well as the efficiency in performance in extremely cold conditions, making it the best possible choice over other types.
 

Since ball valves can be used under high pressure and low temperature, it ensures the operational safety and improves the efficiency of production under pharmaceuticals. According to the International Gas Union (IGU), the global pharmaceutical market is projected to grow at a CAGR of 5.8% during the forecast period, fuelled by rising demand in sectors like healthcare. biopharma, energy, and manufacturing. This growth has directly influenced the adoption of cryogenic ball valves, which are critical for maintaining system integrity in these applications.
 

• Major corporations such as Emerson Electric Co., Flowserve Corporation, and Schlumberger Limited are working to develop innovative solutions to meet changing demands. For instance, Emerson produces ball valves that are made for use in extremely cold conditions to help ensure reliability in this operational context. Additionally, companies like Air Liquide and Linde PLC began to collectively use more advanced ball valves in their operations to improve safety and efficiency with pharmaceutical products and other materials.
   
• Government investment is supporting the ball valve market as well, especially for hydrogen production and storage. For example, the United States Department of Energy invested $8 billion from 2021 to 2023 allocated under the Infrastructure Investment and Jobs Act to develop clean hydrogen hubs in the U.S. This attention to hydrogen fuel points to the critical nature of valve systems to manage hydrogen and other materials from the pharmaceutical industry safely.
   
• Lastly, diaphragm valves account for 26.1% of the market share due to their compactness, ability to handle high temperature and high-pressure requirements, and for being cost effective. Spending is also up 7% on water infrastructure according to the American Water Works Association (AWWA), that has spurred an increase in demand for water applications and treatment processes in the pharmaceutical industry. Their contribution to the industry, in particular, demonstrates the growing utility of valves in the pharmaceutical sector.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channels, the market is segmented direct and indirect. The direct segment held the largest share, accounting for 65% of the cryogenic valve for pharmaceutical market share in 2024.
 

• Direct channels ensure superior quality in product supplements for customers and foster beneficial customer relationships. By cutting out the middleman, companies provide lower costs serve as an operational advantage while also supporting the growing demands of pharmaceutical applications that require temperature control.
   
• Key players like Emerson Electric Co., Parker Hannifin Corporation, and Flowserve Corporation are key players in this expansion. For example, Emerson Electric Co. noted 12% sales growth in cryogenic valves in 2023 attributable to strong innovation and direct engagement with customers.
   
• Similarly, Parker Hannifin Corporation has established a direct distribution network, supporting the increasing demand for cryogenic applications in pharmaceutical cold chain logistics. Investments of this kind are becoming important to the expansion of the growing market.
   
• The U.S. FDA stated that 80% of temperature sensitive pharmaceuticals rely on continuous cold chain integrity. By obtaining valves directly from manufacturers, companies have assurance of traceability, proper documentation, compliance with federal regulators, like ASME-BPE, FDA, and ISO 15848; all of which are key to audits and validation.
   
• Direct procurement channels enable pharmaceutical firms to collaborate intimately with valve manufacturers, leading to integrated solutions that help improve efficiency. These include oxygen-cleaned valves, extended bonnets, and low-emission designs, all meticulously crafted for sterile environments.
   

Based on the application, the market is segmented into bioprocessing and biopharmaceutical, vaccine storage and cold chain, cell and gene therapy, freeze drying and others. In 2024, the bioprocessing segment held a major market share, generating a revenue of USD 215.3 million.
 

• One factor contributing to this is the increasing adoption of cryogenic valves in bioprocessing applications, driven by increasing demand for biologics and biosimilars. The need for precise temperature management and acceptable storage mechanisms also reinforces this leading position.
   
• The market is breakdown by applications which include bioprocessing and bio-pharma, vaccine storage and cold chain, cell and gene therapy, freeze drying and others. Bioprocessing continues to represent key share of the market spurred by advancements in biopharmaceutical manufacturing processes and increased emphasis on product integrity during manufacturing and storage.
   

Looking for region specific data?

Download Free PDF

In 2024, the U.S contributed significantly to the cryogenic valve for pharmaceutical market growth in North America, accounting for 78.8% share in the region.
 

• This growth is supported by U.S. government's strong support for the pharmaceutical industry further bolsters this growth. According to the Congressional Budget Office, federal spending on pharmaceutical research and development exceeded USD 70 billion in recent years, fostering advancements in cryogenic solutions. Additionally, the increasing demand for temperature-sensitive drug storage and transportation has amplified the need for cryogenic valves, solidifying the U.S. as a market leader.
   
• Moreover, the U.S. Food and Drug Administration (FDA) has been actively promoting the adoption of advanced storage and handling systems to ensure the safety and efficacy of biopharmaceuticals. This regulatory push, combined with the growing pipeline of biologics and vaccines, has created a favourable environment for the cryogenic valve market to thrive in the country.
   

Asia Pacific market in 2024 is the fastest growing market in the region and is expected to grow at 8.2% CAGR during the forecast period.
 

• The Asia Pacific cryogenic valve market for pharmaceutical is growing rapidly in 2024 due to increasing industrialization and urbanization, particularly in countries like China and India. For instance, China's pharmaceutical market is expanding significantly, with the country accounting for over 30% of the global pharmaceutical demand with increasing applications in sectors such as healthcare and energy.
   

Europe cryogenic valve for pharmaceutical market is expected to grow at 7.1% CAGR during the forecast period.
 

• This growth is driven by the increasing demand for pharmaceutical across sectors such as healthcare, food and beverage, and energy. In 2023, Europe accounted for approximately 30% of the global medical oxygen consumption. Additionally, the region's focus on renewable energy, particularly hydrogen-based energy systems, has further fueled the market. The European Union's Hydrogen Strategy aims to install at least 40 GW of electrolyzer by 2030, creating substantial opportunities for cryogenic valves.
   

Middle East and Africa cryogenic valve for pharmaceutical market is expected to grow at 6.1% growth rate during the forecast period.      
 

• Technological advancements have significantly transformed the pharmaceutical market in the Middle East and Africa, driving innovation in cryogenic valves to meet the region's growing demand for precision and reliability. These valves are critical for preserving the integrity of temperature-sensitive materials, ensuring product quality and adherence to regulatory standards. With the increasing focus on modernizing pharmaceutical processes and infrastructure in the region, the demand for advanced cryogenic valve solutions is expected to rise steadily
   

Cryogenic Valve for Pharmaceutical Market Share

The top companies in the cryogenic valve for pharmaceutical industry include Baker Hughes, Parker Hannifin, Emerson, Crane Company and Flowserve and collectively hold a share of 42% in the market. These prominent players are proactively involved in strategic endeavors, such as mergers & acquisitions, facility expansions & collaborations, to expand their product portfolios, extend their reach to a broad customer base, and strengthen their market position.
 

• Baker Hughes provides specialized cryogenic valve solutions for pharmaceutical-grade gases such as oxygen, nitrogen, and hydrogen. These valves are engineered to ensure reliable sealing, reduced emissions, and long-term durability. They are widely used in air separation units and medical gas systems, supporting safety and compliance in pharmaceutical operations.
   
• Parker Hannifin supplies high-purity cryogenic valves through its Bestobell and Veriflo product lines, tailored for pharmaceutical and medical gas applications. These valves are designed for excellent thermal stability, corrosion resistance, and leak-tight performance. They support sterile environments and adhere to FDA and ISO standards, ensuring reliability in critical processes.
   
• Emerson offers advanced cryogenic valves through its Fisher, AEV, and ASCO brands, designed for ultra-low temperature pharmaceutical processes. These valves deliver precise control, low emissions, and dependable performance. With integrated diagnostics and compliance with ASME-BPE and FDA standards, they enhance automation, safety, and efficiency in biotech and pharmaceutical facilities.
   

Cryogenic Valve for Pharmaceutical Market Companies

Major players operating in the global cryogenic valve for pharmaceutical industry are:

• Baker Hughes
• Bray International
• Crane Company
• Emerson
• Flowserve
• Herose
• Kitz
• Microfinish
• Parker Hannifin
• PK Valve and Engineering
• Powell Valves
• Rego
• Swagelok
• Trimteck
• Velan
   

Crane Company delivers advanced cryogenic valve solutions designed specifically for the pharmaceutical market, focusing on hydrogen, oxygen, and nitrogen systems. The product range includes bellows seal globe valves, lift-check valves, and vacuum jacketed piping systems, all crafted to perform reliably under extreme cryogenic conditions. These solutions provide zero-leakage performance, reduced heat transfer, and long-lasting durability, ensuring optimal functionality for critical applications, certified to meet stringent industry standards.
 

Flowserve, is a company in valve technology, offers a comprehensive range of cryogenic valves, including Worcester ball valves and Valtek control valves, specifically designed for ultra-low temperature applications in the pharmaceutical and biotech industries. These valves deliver reliable tight shutoff, reduced emissions, and exceptional purity performance. Flowserve’s solutions are integral to sterile gas handling, cold chain logistics, and bioprocessing systems, ensuring compliance with rigorous ASME-BPE and FDA standards to meet industry demands effectively.
 

Cryogenic Valve for Pharmaceutical Industry News

• In October 2025, Baker Hughes announced its acquisition of Chart Industries through an all-cash transaction. Expected to close by mid-2026, subject to regulatory approvals, this acquisition strategically enhances Baker Hughes' capabilities in the pharmaceutical and cryogenic markets. By integrating Chart’s expertise in valves, tanks, and process equipment essential for hydrogen, oxygen, and carbon capture, Baker Hughes aims to strengthen its Industrial & Energy Technology division.
   
• In September 2025, KITZ announced its entry into the green hydrogen market with the development of PEM water electrolysis valves. These valves are designed to handle cryogenic and high-purity gases, including oxygen and hydrogen, ensuring compatibility with pharmaceutical-grade gas systems. While primarily focused on energy applications, this technology aligns with the needs of the pharma market, addressing its demand for precision and reliability.
   
• In July 2025, Herose launched the QuarterT cryogenic ball valve, tailored for pharmaceutical and biological applications involving oxygen, nitrogen, and CO2. Designed to perform at temperatures as low as –196°C, the valve delivers high flow rates and ensures a long service life, meeting the rigorous demands of the pharma market. Its ergonomic handle and low torque operation enhance usability, while durability testing for 2,000 cycles underscores its reliability.
   
• In March 2025, Framatome completed its acquisition of Velan SAS, rebranding it as Valserve. This acquisition enhances Framatome’s capabilities in cryogenic and nuclear valve technologies, with a strong focus on healthcare and pharmaceutical applications. Velan’s cryogenic valves, widely used in medical gas systems and pharmaceutical-grade applications, complement Framatome’s portfolio and expertise.
   
• In February 2025, Flowserve introduced the Worcester Cryogenics Series, targeting the LNG, hydrogen, and medical gas markets. These floating ball valves are engineered for ultra-low temperature applications, offering superior sealing integrity and reliability. Specifically designed for pharmaceutical-grade oxygen and nitrogen systems, the valves address the stringent requirements of the healthcare and biotech sectors.
   

The cryogenic valve for pharmaceutical market research report includes in-depth coverage of the industry, with estimates & forecast in terms of revenue and volume (USD Million) (Thousand Units) from 2021-2034, for the following segments:

Click here to Buy Section of this Report

Market, By Valve Type

• Ball valves
• Diaphragm valves
• Globe valve
• Check valve
• Others (relief, safety, solenoid valve etc.)

Market, By Valve Size

• Less than 1 inch
• Between 1 to 4 inches
• Between 4 to 8 inches
• More than 8 inches

Market, By Application

• Bioprocessing and biopharmaceutical
• Vaccine storage and cold chain
• Cell and gene therapy
• Freeze drying
• Others (medical gas, cryopreservation etc.)

Market, By Distribution Channel

• Direct
• Indirect

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE